MIVS technique continues to evolve

Article

Retinal surgeons refine technology, instrumentation to optimize safety and efficacy

Microincision vitrectomy surgery (MIVS) is changing the way that vitreoretinal specialists operate. As with any new technology, MIVS has a number of significant advantages, as well as a few new challenges.

Overall, patients come in on postoperative day 1 usually with minimal to no discomfort and they are not usually troubled by slowly dissolving Vicryl sutures rubbing under their eyelids for two weeks. Because the incisions into the conjunctiva are smaller, there is less bleeding, which results in a better cosmetic appearance (still not as good as after cataract surgery, but for a retina surgeon, it is pretty good).

From the surgeon's perspective, there are a number of advantages to MIVS. For most cases, MIVS is faster than standard 20 G vitrectomy. With the previous-generation MIVS systems, especially 25 G, vitrectomy removal took longer, but the time saved in opening and closing the eye made the overall surgical time for 'straight-forward' cases about the same or somewhat less than 20 G vitrectomy.

The new-generation MIVS systems offer 5,000 cuts-per-minute. The surgeon is able to remove the vitreous remarkably efficiently, and the vitrectomy time is better than with standard 20 G vitrectomy. For those accustomed to 20 G systems, a 20 G 5,000 cuts-per-minute probe is available, but given how efficient the MIVS systems are at this rate, 20 G vitrectomy does not distinguish itself.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
© 2025 MJH Life Sciences

All rights reserved.